# Compare BPC-157, TB-500, GHK-Cu and KPV — Sovereign Peptides

> A side-by-side comparison of four Recovery & Tissue Repair research peptides — BPC-157, TB-500, GHK-Cu and KPV — across peptide class, evidence base, administration studied, regulatory status and key cautions.

Where the four repair peptides converge, where they diverge, and — most importantly — how far the evidence behind each one actually reaches.

## The short version

This page lines up [BPC-157](/bpc-157), [TB-500](/tb-500), [GHK-Cu](/ghk-cu) and [KPV](/kpv) on the dimensions that matter most when reading research peptides: what kind of molecule each one is, where it has been studied most, how strong that evidence is, how it was given in studies, its regulatory standing, and its single biggest caution. The headline is simple. All four are studied for recovery and tissue repair, but they are at very different stages: GHK-Cu has the most human (mostly topical) data, BPC-157 has the deepest animal record with three tiny human pilots, TB-500's evidence largely belongs to a bigger parent protein, and KPV has no human trials at all. None is an approved medicine, and none is presented here with a human dose.

## The comparison matrix

| Dimension | BPC-157 | TB-500 | GHK-Cu | KPV |
| --- | --- | --- | --- | --- |
| Peptide class | Stable gastric pentadecapeptide (15 aa) | Synthetic actin-binding fragment of thymosin beta-4 (7 aa) | Copper-binding tripeptide / copper tripeptide-1 (3 aa) | Melanocortin-derived anti-inflammatory tripeptide (3 aa) |
| Most-studied in | Tendon, gut, muscle and nerve repair | Actin biology; cell migration and angiogenesis | Skin regeneration and matrix synthesis | Gut inflammation (colitis) |
| Evidence base (model) | Mostly rat; 3 small human pilots [2] | Mostly full-length Tβ4 (animal + 1 human Phase 1) [8][11] | In vitro + small human topical trials [16] | In vitro + mouse only; no human trials [20] |
| Administration studied | IM, intragastric, drinking water, IV pilot [3][5] | IV (full-length Tβ4), IP in animals [9][11] | Topical, ex vivo skin penetration [13][17] | Oral / PepT1-targeted delivery in mice [19][20] |
| Regulatory / WADA status | Not approved; WADA S0 prohibited | Not approved; WADA-prohibited | Cosmetic ingredient (topical); systemic unapproved | Not approved; not specifically WADA-listed |
| Key caution | Single-lab, preclinical-heavy record [2] | Fragment vs full-protein identity gap [8] | Poor skin permeability; pigmentation risk [13] | Entirely preclinical; no human PK [20] |

## Peptide class

The four span a size range. BPC-157 is the largest at fifteen amino acids, a stable gastric pentadecapeptide. TB-500 is a seven-amino-acid fragment carrying the actin-binding motif of the much larger thymosin beta-4 protein. GHK-Cu and KPV are both tripeptides (three amino acids), but they could hardly be more different in character: GHK-Cu is a *copper carrier* drawn from collagen, while KPV is the anti-inflammatory tail of the hormone alpha-MSH [22].

## Most-studied in

Each peptide has a home territory. BPC-157's animal record is broadest, spanning tendon, gut, muscle and nerve [6]. TB-500's research centers on actin biology and the cell migration and angiogenesis that follow from it [10]. GHK-Cu is overwhelmingly a skin-and-matrix story — collagen, elastin and the dermal environment [16]. KPV is studied almost entirely in models of gut inflammation, particularly chemically induced colitis in mice [20].

## Evidence base (model)

This is where the four genuinely separate. GHK-Cu has the most human data, but it is mostly topical and small-scale, plus one 45-patient combination hair-loss trial [15][16]. BPC-157 has a deep, decades-long animal record and three small uncontrolled human pilots [2]. TB-500 is the trickiest: its strongest human data — a Phase 1 IV safety study in 40 volunteers — used full-length thymosin beta-4, not the marketed fragment [8][11]. KPV has the least human footing of all: no published human clinical trials, only cell and mouse work [20].

## Administration studied

Routes track the research questions. BPC-157 has been studied intramuscularly, intragastrically, in drinking water, and in a tiny intravenous human safety pilot [3][5]. TB-500 / Tβ4 work used intravenous dosing in the human Phase 1 study and intraperitoneal dosing in animals [9][11]. GHK-Cu is studied topically, with ex vivo skin-penetration measurements quantifying how much copper crosses the skin [13][17]. KPV's recent work is dominated by oral and PepT1-targeted nanoparticle delivery in mice, because the free peptide is fragile [19][20].

## Regulatory / WADA status

None of the four is an FDA- or EMA-approved medicine for systemic use. BPC-157 and TB-500 are both explicitly prohibited in sport by WADA (BPC-157 under the S0 non-approved-substances category) [8]. GHK-Cu is unusual: topical copper tripeptide-1 is a legal, widely sold cosmetic ingredient, while injectable or systemic GHK-Cu is unapproved and research-only [13]. KPV is not specifically listed by name on the WADA Prohibited List, but as a non-approved peptide it should still be treated cautiously in any sport context.

## Key caution

Each peptide carries a defining caveat. For BPC-157 it is that the broad, internally consistent signal lives mostly in one lab's rodents, with only three tiny human pilots [2]. For TB-500 it is the identity gap — the marketed fragment is not the molecule behind most of the efficacy data, plus a theoretical tumor-angiogenesis signal from the parent protein [8][10]. For GHK-Cu it is poor skin permeability and a documented risk of localized hyperpigmentation [13]. For KPV it is that the entire literature is preclinical, with no validated human pharmacokinetics [20]. Reading them together, the lesson is consistent: promising mechanisms, uneven and often early evidence.

---

A cross-referenced reading desk for recovery-peptide research — citations, not prescriptions, and never a product for sale.